Trends in Utilization of Guideline-Directed Cardiorenal Protective Therapies for Chronic Kidney Disease in Patients with Cardiovascular Morbidity: Real World Data from Two Cross-Sectional Snapshots (HECMOS I and II)

<b>Introduction:</b> Chronic kidney disease (CKD) affects roughly 10% of the global population and significantly increases cardiovascular risk. While renin–angiotensin system inhibitors (RASi) remain a therapeutic mainstay, recent evidence supports the renoprotective value of sodium–glucose cotransp...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Panagiotis Theofilis, Ioannis Leontsinis, Dimitrios Farmakis, Dimitrios Avramidis, Nikolaos Argyriou, Matthaios Didagelos, Ioannis Zarifis, Costas Thomopoulos, Anastasia Kitsiou, Georgios Koutsopoulos, George Kourgianidis, Athanasios Kostopoulos, Eleni Manta, Maria Marketou, Vasiliki Bistola, George Bibis, Katerina K. Naka, Periklis Ntavlouros, Evangelos Oikonomou, Sotirios Patsilinakos, Nikolaos Patsourakos, Asaf Sawafta, Vaios Schismenos, Athanasios Trikas, Georgios Chalikias, Christos Chatzieleftheriou, Konstantinos Tsioufis
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	MDPI AG 2025-08-01
Serie:	Biomedicines
Soggetti:	chronic kidney disease finerenone heart failure SGLT2 inhibitor
Accesso online:	https://www.mdpi.com/2227-9059/13/8/1987
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!